Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study.

ABSTRACT:

Objective

To evaluate the effect of adalimumab on the frequency of anterior uveitis (AU) flares in patients with active ankylosing spondylitis (AS).

Methods

We determined the history of ophthalmologist-diagnosed AU in 1250 patients with active AS who were enrolled in a multinational, open-label, uncontrolled clinical study of treatment with adalimumab, 40 mg every other week for up to 20 weeks. All AU flares were documented throughout the adalimumab treatment period plus 70 days. We compared the rates of AU flares per 100 patient years (PYs) reported during the year before adalimumab treatment with rates during adalimumab treatment, in total and by patient subgroups.

Results

The AU flare rates before adalimumab treatment were 15/100 PYs in all patients (n = 1250), 68.

SUBMITTER: Rudwaleit M 

PROVIDER: S-EPMC2663712 | biostudies-literature | 2009 May

REPOSITORIES: biostudies-literature